FDA grants "Breakthrough Device" designation to Lumitron's HyperVIEW cancer detection X-Ray System

Breakthrough status announced on World Cancer Day (Feb. 4)

Irvine, CA – The U.S. Food & Drug Administration (FDA) has granted Lumitron Technologies, Inc. the designation of “Breakthrough Device” for its HyperVIEW X-Ray system utilizing the K-Edge subtraction technique to enable contrast-enhanced imaging for diagnosis of breast cancer. This technology utilizes Lumitron’s proprietary distributed charge laser-Compton technology to provide imaging that is both 100 times higher resolution and significantly safer than standard X-Rays.

“Being listed in the FDA’s Breakthrough Device Program will enable Lumitron’s HyperVIEW X-Ray system to accelerate through the approval process and hopefully bring this revolutionary technology to the clinic faster,” said Dr. Chris Barty, co-founder and Chief Technology Officer of Lumitron.

Peer-reviewed studies published by Frontiers In Physics show that HyperVIEW is the world’s highest-resolution, compact mono-energetic, x-ray imaging system.  It has the promise of forever changing the way breast cancer is detected. 

The breakthrough designation was confirmed by the FDA on January 27th and announced by Lumitron Technologies, Inc. on February 4th, World Cancer Day.

Lumitron NR - FDA grants breakthrough status to HyperVIEW V5.pdf

Download PDF • 112KB

###